AI BioTech will use the management system to gain complete visibility into revenue and billing system activity, test ordering patterns, payor specific reimbursement and provide technological guidance which will results in significant gains in cash and bad debt reductions.

AI BioTech CEO Bill Miller said XIFIN was the clear choice because the company has a solid reputation for achieving results, powerful web service technology for change advocacy and reform in the molecular DX and diagnostic services market.

"We are confident that our partnership with XIFIN will provide the framework we need to strategically manage our operations and drive growth and profitability," Miller said.

AI BioTech provides integrated research and development and clinical testing services to physicians and life sciences investigators at biotechnology and pharmaceutical companies, academic institutions and government agencies in support of bringing new products to market.